News | May 02, 2026
Merck posts mixed Q1 2026 results as blockbuster drugs drive growth
But acquisition charges drag earnings into loss
But acquisition charges drag earnings into loss
The transaction marks a clear portfolio reshuffle for Indoco
While Drugs for Neglected Diseases initiative (DNDi) drives the R&D for neglected diseases, we collaborate with pharmaceutical companies at multiple stages, including sourcing promising molecules
His appointment is expected to further strengthen the company’s financial governance and regional operational strategy across South Asia
Tamir brings more than 20 years of experience in the medical technology sector
Study introduces structured, condition-specific emergency coding system to improve coordination, response time, and patient safety in tertiary care hospitals
Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada
SPARC enters definitive agreement to monetise rare paediatric disease PRV, unlocking capital for R&D and strategic growth
New medical and wellness centre combines on-site care with telehealth to support industrial workforce and surrounding communities
Landmark agreement opens market access, mobility pathways, and institutional collaboration for Ayurveda, Yoga, and holistic healthcare services
Subscribe To Our Newsletter & Stay Updated
